Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Serine and Methionine Metabolism: Vulnerabilities in Lethal Prostate Cancer.

Gao X, Locasale JW, Reid MA.

Cancer Cell. 2019 Mar 18;35(3):339-341. doi: 10.1016/j.ccell.2019.02.014.

PMID:
30889375
2.

Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer.

Reina-Campos M, Linares JF, Duran A, Cordes T, L'Hermitte A, Badur MG, Bhangoo MS, Thorson PK, Richards A, Rooslid T, Garcia-Olmo DC, Nam-Cha SY, Salinas-Sanchez AS, Eng K, Beltran H, Scott DA, Metallo CM, Moscat J, Diaz-Meco MT.

Cancer Cell. 2019 Mar 18;35(3):385-400.e9. doi: 10.1016/j.ccell.2019.01.018. Epub 2019 Feb 28.

PMID:
30827887
3.

Characterization of the usage of the serine metabolic network in human cancer.

Mehrmohamadi M, Liu X, Shestov AA, Locasale JW.

Cell Rep. 2014 Nov 20;9(4):1507-19. doi: 10.1016/j.celrep.2014.10.026. Epub 2014 Nov 6.

4.

Serine Is an Essential Metabolite for Effector T Cell Expansion.

Ma EH, Bantug G, Griss T, Condotta S, Johnson RM, Samborska B, Mainolfi N, Suri V, Guak H, Balmer ML, Verway MJ, Raissi TC, Tsui H, Boukhaled G, Henriques da Costa S, Frezza C, Krawczyk CM, Friedman A, Manfredi M, Richer MJ, Hess C, Jones RG.

Cell Metab. 2017 Feb 7;25(2):345-357. doi: 10.1016/j.cmet.2016.12.011. Epub 2017 Jan 19. Erratum in: Cell Metab. 2017 Feb 7;25(2):482.

5.

The hallmarks of castration-resistant prostate cancers.

Katsogiannou M, Ziouziou H, Karaki S, Andrieu C, Henry de Villeneuve M, Rocchi P.

Cancer Treat Rev. 2015 Jul;41(7):588-97. doi: 10.1016/j.ctrv.2015.05.003. Epub 2015 May 9. Review.

PMID:
25981454
6.

Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.

Sainio M, Visakorpi T, Tolonen T, Ilvesaro J, Bova GS.

Pathol Res Pract. 2018 Jun;214(6):848-856. doi: 10.1016/j.prp.2018.04.015. Epub 2018 Apr 26.

PMID:
29728311
7.
8.

Extracellular pH Modulates Neuroendocrine Prostate Cancer Cell Metabolism and Susceptibility to the Mitochondrial Inhibitor Niclosamide.

Ippolito JE, Brandenburg MW, Ge X, Crowley JR, Kirmess KM, Som A, D'Avignon DA, Arbeit JM, Achilefu S, Yarasheski KE, Milbrandt J.

PLoS One. 2016 Jul 20;11(7):e0159675. doi: 10.1371/journal.pone.0159675. eCollection 2016.

9.

Regulation of enzymes of serine and one-carbon metabolism by testosterone in rat prostate, liver, and kidney.

Sanborn TA, Kowle RL, Sallach HJ.

Endocrinology. 1975 Oct;97(4):1000-7.

PMID:
172314
10.
11.

ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.

Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR.

Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26.

PMID:
30478421
12.

Clinical and molecular features of treatment-related neuroendocrine prostate cancer.

Akamatsu S, Inoue T, Ogawa O, Gleave ME.

Int J Urol. 2018 Apr;25(4):345-351. doi: 10.1111/iju.13526. Epub 2018 Feb 3. Review.

13.

[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].

Campedel L, Kossaï M, Blanc-Durand P, Rouprêt M, Seisen T, Compérat E, Spano JP, Malouf G.

Bull Cancer. 2017 Sep;104(9):789-799. doi: 10.1016/j.bulcan.2017.05.007. Epub 2017 Jun 30. French.

PMID:
28673439
14.

Serine and glycine metabolism in cancer.

Amelio I, Cutruzzolá F, Antonov A, Agostini M, Melino G.

Trends Biochem Sci. 2014 Apr;39(4):191-8. doi: 10.1016/j.tibs.2014.02.004. Epub 2014 Mar 20. Review.

15.

Molecular model for neuroendocrine prostate cancer progression.

Chen R, Dong X, Gleave M.

BJU Int. 2018 Oct;122(4):560-570. doi: 10.1111/bju.14207. Epub 2018 Apr 24. Review.

PMID:
29569310
16.

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.

Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26.

17.

Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer.

Tamura K, Furihata M, Chung SY, Uemura M, Yoshioka H, Iiyama T, Ashida S, Nasu Y, Fujioka T, Shuin T, Nakamura Y, Nakagawa H.

Cancer Sci. 2009 May;100(5):914-9. doi: 10.1111/j.1349-7006.2009.01117.x. Epub 2009 Feb 26.

18.

Prostate tumor neuroendocrine differentiation via EMT: The road less traveled.

Dicken H, Hensley PJ, Kyprianou N.

Asian J Urol. 2019 Jan;6(1):82-90. doi: 10.1016/j.ajur.2018.11.001. Epub 2018 Nov 17. Review.

19.

Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma.

Ducker GS, Ghergurovich JM, Mainolfi N, Suri V, Jeong SK, Hsin-Jung Li S, Friedman A, Manfredi MG, Gitai Z, Kim H, Rabinowitz JD.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11404-11409. doi: 10.1073/pnas.1706617114. Epub 2017 Oct 9.

20.

Amino acid cross resistance in Agrobacterium tumefaciens.

BEARDSLEY RE.

J Bacteriol. 1962 Dec;84:1237-40.

Supplemental Content

Support Center